What it is (overview)

The ZN Stain - AFB (Ziehl–Neelsen stain for Acid-Fast Bacilli) is a classic microscopy-based laboratory test used to look for mycobacteria in a clinical sample. Mycobacteria (such as Mycobacterium tuberculosis, the germ that causes tuberculosis (TB)) have a waxy outer coating that makes them “acid-fast.” This means they hold onto a special red dye even after an acid wash, allowing the lab to see them under a microscope.

The test does not measure a chemical level in the blood. Instead, it checks whether AFB are present in the specimen and may provide a semi-quantitative estimate (often reported as “rare,” “1+,” “2+,” “3+,” etc.), which reflects how many organisms are seen.

What results mean (in plain language):

• AFB not seen / negative smear: No acid-fast bacilli were seen on the slide. This lowers the likelihood of contagious pulmonary TB, but it does not fully rule out TB or other mycobacterial infection—especially if symptoms and imaging strongly suggest it. Additional testing (like mycobacterial culture or molecular tests such as NAAT/GeneXpert) may still be needed.
• AFB seen / positive smear: Acid-fast bacilli were observed. This supports a diagnosis of TB or another mycobacterial infection and may indicate a higher chance of transmission when the sample is sputum from the lungs. Because the stain cannot reliably identify the exact species, confirmatory tests (culture and/or molecular testing) are usually performed to determine whether it is M. tuberculosis or another type of mycobacteria.
• Smear grading (if provided): Higher grades generally suggest a higher bacterial load, which can correlate with greater infectiousness (for lung samples) and may help clinicians monitor response to treatment over time.

Common sample types include a sputum test (mucus coughed up from the lungs), bronchoalveolar lavage fluid, lymph node or tissue samples, pleural fluid, or other body fluids depending on the suspected site of infection.

When & why it's usually done

Your clinician may order a ZN stain for AFB when there is concern for TB or another mycobacterial infection—especially infections affecting lung health. It is often used as an initial, rapid test because microscopy can provide results faster than culture.

Symptoms that may prompt testing include:

• A cough lasting 2–3 weeks or longer
• Coughing up blood (hemoptysis) or rust-colored sputum
• Chest pain, shortness of breath, or persistent wheezing
• Fever, night sweats, chills
• Unexplained weight loss, loss of appetite, fatigue

Situations and risk factors where AFB testing is commonly used:

• Abnormal chest X-ray or CT scan suggestive of TB
• Close contact with someone diagnosed with active pulmonary TB
• Living or working in higher-risk settings (e.g., shelters, correctional facilities, long-term care facilities)
• Weakened immune system (e.g., HIV, organ transplant, long-term steroids, certain biologic medications)
• History of prior TB or incomplete TB treatment
• Symptoms suggesting TB outside the lungs (e.g., persistent swollen lymph nodes, spine pain, prolonged fever of unknown cause)

This diagnostic test may also be ordered to help monitor treatment response in people already diagnosed with pulmonary TB, especially when sputum smear results were initially positive.

Common diseases related to it

• Pulmonary tuberculosis (TB)
• Extrapulmonary tuberculosis (e.g., lymph node TB, pleural TB, bone/spine TB, TB meningitis)
• Nontuberculous mycobacterial (NTM) lung disease (e.g., Mycobacterium avium complex)
• Disseminated mycobacterial infection (more common in immunocompromised people)
• Mycobacterial lymphadenitis (swollen lymph nodes due to mycobacteria)
• Skin and soft tissue mycobacterial infections (certain NTM species)

Health goals where it may help

• Early detection of tuberculosis to reduce complications and protect close contacts
• Assessing infectiousness in suspected pulmonary TB (especially when sputum AFB is positive)
• Guiding next-step testing (e.g., mycobacterial culture and molecular TB tests for confirmation)
• Monitoring response to TB treatment through follow-up sputum microscopy in appropriate cases
• Supporting respiratory/lung health evaluation when chronic cough and abnormal imaging suggest a bacterial infection such as TB
• Improving infection control decisions in clinical or hospital settings (isolation precautions when TB is suspected)